Home › IGA Glomerulonephritis
IGA Glomerulonephritis clinical trials recruiting in the U.S.
18 studies for IGA Glomerulonephritis are recruiting participants at sites across the United States.
Cities with the most studies
- Houston, TX9 studies
- Denver, CO5 studies
- Orlando, FL5 studies
- Los Angeles, CA4 studies
- Sioux City, IA4 studies
- Cedar Rapids, IA3 studies
- Boston, MA3 studies
- Philadelphia, PA3 studies
- New York City, NY3 studies
- Johns Creek, GA3 studies
- Columbus, OH3 studies
By state
- California8 studies
- Colorado7 studies
- Florida10 studies
- Georgia5 studies
- Iowa3 studies
- Massachusetts3 studies
- Michigan4 studies
- Minnesota3 studies
- New York5 studies
- Ohio4 studies
- Pennsylvania3 studies
- South Dakota4 studies
- Tennessee3 studies
- Texas9 studies
Recently updated studies
A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
RecruitingPhase 2
Ages 18 to 60 · All sexes · Updated Sep 25, 2026 · NCT07541287Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
RecruitingPhase 3
Ages 2 to 18 · All sexes · Updated Sep 21, 2026 · NCT07498335A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06935357Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
RecruitingPhase 3
Ages 2 to 18 · All sexes · Updated Sep 9, 2026 · NCT06994845Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06989359Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 17, 2026 · NCT06858319A Study to Assess the Effects of Zigakibart on IgA Nephropathy.
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Aug 10, 2026 · NCT07146906A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
RecruitingPhase 2
Ages 16 and older · All sexes · Updated Aug 4, 2026 · NCT06419205Study of WAL0921 in Patients With Glomerular Kidney Diseases
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Aug 3, 2026 · NCT06466135Study of Ravulizumab in Pediatric Participants With Primary IgAN
RecruitingPhase 3
Ages 2 to 18 · All sexes · Updated Jul 30, 2026 · NCT07024563Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
RecruitingPhase 2
Ages 18 to 99 · All sexes · Updated Jul 29, 2026 · NCT06797518Atacicept in Multiple Glomerular Diseases
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 26, 2026 · NCT06983028Study of BHV-1400 in IgA Nephropathy
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jun 23, 2026 · NCT07054684Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
RecruitingPhase 2
Ages 1 to 17 · All sexes · Updated May 12, 2026 · NCT05003986Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 3, 2025 · NCT06676579A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 17, 2025 · NCT06952426Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue
RecruitingPhase 2
Ages 16 and older · All sexes · Updated Apr 6, 2025 · NCT06740526Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 4, 2025 · NCT01802034From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.